OptimizeRx | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 26.07 M

Revenue: As of FY2025 Q3, the actual value is USD 26.07 M, beating the estimate of USD 24.79 M.

EPS: As of FY2025 Q3, the actual value is USD 0.04, beating the estimate of USD -0.096.

EBIT: As of FY2025 Q3, the actual value is USD 3.113 M.

Net Revenue: $26,067 for the three months ended September 30, 2025, compared to $21,309 for the same period in 2024. For the nine months ended September 30, 2025, net revenue was $77,190 compared to $59,811 for the same period in 2024.

Gross Profit: $17,516 for the three months ended September 30, 2025, compared to $13,447 for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $49,495 compared to $37,355 for the same period in 2024.
Operating Expenses: $15,466 for the three months ended September 30, 2025, compared to $22,009 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $46,371 compared to $54,695 for the same period in 2024.
Net Income (Loss): $779 for the three months ended September 30, 2025, compared to - $9,124 for the same period in 2024. For the nine months ended September 30, 2025, net income was $112 compared to - $20,032 for the same period in 2024.
Income (Loss) from Operations: $2,050 for the three months ended September 30, 2025, compared to - $8,562 for the same period in 2024. For the nine months ended September 30, 2025, income from operations was $3,124 compared to - $17,340 for the same period in 2024.

Net Cash Provided by Operating Activities: $11,627 for the nine months ended September 30, 2025, compared to $4,691 for the same period in 2024.
Net Cash Used in Investing Activities: - $138 for the nine months ended September 30, 2025, compared to - $330 for the same period in 2024.
Net Cash Used in Financing Activities: - $5,350 for the nine months ended September 30, 2025, compared to - $2,087 for the same period in 2024.

Average Revenue per Top 20 Pharmaceutical Manufacturer: $3,073 for the twelve months ended September 30, 2025, compared to $2,874 for the same period in 2024.
Percent of Total Revenue Attributable to Top 20 Pharmaceutical Manufacturers: 56% for the twelve months ended September 30, 2025, compared to 65% for the same period in 2024.
Net Revenue Retention: 120% for the twelve months ended September 30, 2025, compared to 127% for the same period in 2024.
Revenue per Average Full-Time Employee: $820,000 for the twelve months ended September 30, 2025, compared to $732,000 for the same period in 2024.

Core Business Focus: OptimizeRx aims to grow its existing customer base and generate more consistent revenues through a shift towards enterprise-level engagements and innovative proprietary virtual communication solutions such as Micro-Neighborhood Targeting and the AI-powered Dynamic Audience Activation Platform (DAAP). The company expects these strategies to increase margins and profitability over time.
Non-Core Business: The company is also focusing on transitioning DAAP customers to a subscription-based model for data services to improve margins, increase visibility, and enhance revenue predictability.